Market Overview

UPDATE: Deutsche Bank Ups PT to $45 on Medtronic on Top-Line Beat

Share:
Related MDT
UPDATE: Medtronic plc: FDA Approves the VenaSeal Closure System for Treatment of Clinically Symptomatic Venous Reflux
3 Companies That Could Be Negatively Impacted By Johnson & Johnson Sale Of Cordis
Medtronic's VenaSeal Wins FDA Nod for Vericose Veins Cure - Analyst Blog (Zacks)

Deutsche Bank reiterated its Hold rating on Medtronic (NYSE: MDT) and raised its price target from $43 to $45.

Deutsche Bank noted, "In F2Q13, Medtronic's sales grew 5% ex-FX driven by the successful launch and share gains in the drug-eluting stent business (which accounted for 1.6%-pts of growth). While sales were better, EPS was in-line with Consensus ($0.01 below our estimate) due mainly to lower gross margins. Medtronic managed the P&L noting it took one-time gains from selling treasuries and minority investments to help offset FX hedging losses. We maintain our Hold rating but we are slightly increasing our PT to $45 from $43 given the more stable top line performance in the quarter and expectations going forward."

Medtronic closed at $42,65 on Tuesday.

Latest Ratings for MDT

DateFirmActionFromTo
Feb 2015JefferiesMaintainsBuy
Dec 2014Bank of AmericaMaintainsBuy
Nov 2014WedbushMaintainsNeutral

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (MDT)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→